December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Atossa Genetics Inc (NQ: ATOS )

1.870 USD +0.200 (+11.98%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Atossa Genetics Inc

< Previous 1 2 3 Next >
Thinking about buying stock in iBio, Fluidigm Corp, Atossa Therapeutics, BioCryst Pharmaceuticals, or GameStop?
InvestorsObserver issues critical PriceWatch Alerts for IBIO, FLDM, ATOS, BCRX, and GME. 
From PR Newswire
COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay
Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS ), recently shared his latest research and findings regarding the origins of COVID-19... 
From PR Newswire
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market
From GlobeNewswire News Releases
Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market
From GlobeNewswire News Releases
Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering
From GlobeNewswire News Releases
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
From GlobeNewswire News Releases
New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic
A paper published on Zenodo (DOI 10.5281/zenodo.4119263) by Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS), illuminates new... 
From PR Newswire
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
From GlobeNewswire News Releases
Registration Is Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event On October 13, 2020
In honor of October Breast Cancer Awareness Month, Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse will deliver a presentation titled “Atossa Therapeutics: Tackling our Greatest Health... 
From GlobeNewswire News Releases
Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, "Stay Safe: A Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First Family
According to Dr. Quay, MD, PhD, "the book provides lifesaving tips you can't find anywhere else to help you and your family stay safe" 
From PR Newswire
Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020
From GlobeNewswire News Releases
Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study Arm 
From GlobeNewswire News Releases
Physician-Scientist Dr. Steven Quay's "Stay Safe: A Physician's Guide to Survive Coronavirus" Reaches #1 on Five Amazon Bestsellers Lists
"The Guide Offers Simple Tips to Help Protect You and Your Family Against the Coronavirus" 
From PR Newswire
Physician-Scientist Dr. Steven Quay Shares Back-to-School Tips To Stay Safe and Survive Coronavirus
"Simple and Affordable Salt Spray Uses Everyday Household Ingredients to Help Protect You Against the Coronavirus" 
From PR Newswire
Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19
From GlobeNewswire News Releases
New COVID-19 Survival Manual Offers Tips from Renowned Physician Scientist to Keep You and Your Family Healthy During the Pandemic
"The Book Includes Prevention and Treatments Tips to Keep You Safe for Back-to-School, Cold & Flu Season, and Beyond" 
From PR Newswire
Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020
From GlobeNewswire News Releases
Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19
From GlobeNewswire News Releases
Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19
Enrollment Expected to Begin Within 30 days 
From GlobeNewswire News Releases
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence 
From GlobeNewswire News Releases
Registration Is Now Open for Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event on July 30, 2020
Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two COVID-19 treatment programs 
From GlobeNewswire News Releases
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program
From ACN Newswire
Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa’s Second COVID-19 Therapeutic Development Program
From GlobeNewswire News Releases
Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients 
From GlobeNewswire News Releases
Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls
From GlobeNewswire News Releases
Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201
From GlobeNewswire News Releases
Potential Life Saving COVID-19 Survival Manual Removed from Amazon Kindle Store Three Days before Official Launch
Physician-Scientist Dr. Steven Quay, MD, PhD vows to make the book available through his website, with proceeds supporting military veterans performing COVID-19 relief work in their communities 
From PR Newswire
Thinking about buying stock in LATAM Airlines, Atossa Therapeutics, Outlook Therapeutics, Canopy Growth Corp, or Royal Caribbean Cruises?
InvestorsObserver issues critical PriceWatch Alerts for LTM, ATOS, OTLK, CGC, and RCL. 
From PR Newswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.